ResMed FY26: revenue +9.9% to $5.65B, net income +8.8% to $1.52B; $700M buyback, MatrixCare sale

Filed August 13, 2026 · Period ending June 30, 2026 · Compared to 10-K Aug 8, 2025 · ~2 min read

Key Changes

• high

  Net income rose 8.8% to $1.52B (diluted EPS +9.7% to $10.43) on revenue growth of 9.9% to $5.65B, driven by Sleep and Breathing Health (+10%) and Residential Care Software (+5%). Operating income grew 12% to $1.9B despite $42M in Astral field-safety costs and $22M in restructuring charges.

  MD&A: Financial Results verify on EDGAR →
• high

  Signed definitive agreement to divest MatrixCare business for $490M cash (expected Q1 FY27 close). MatrixCare contributed $220M revenue and $28M operating profit in FY26; assets classified as held for sale at $457M.

  MD&A: MatrixCare Divestiture / Notes: Held for Sale verify on EDGAR →
• high

  Acquired Noctrix Health for $335M in June 2026, adding FDA De Novo classified wearable therapeutics for restless legs syndrome. Purchase price allocation includes $118M in intangibles and $202M in goodwill.

  Notes: Noctrix Acquisition verify on EDGAR →